Asensus Surgical Announces Installation of Senhance Surgical System in the Department of Gynecology at University Hospital Tübingen
07 Juillet 2022 - 12:50PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
today announced the installation of a Senhance® Surgical System in
the Department of Gynecology at the University Hospital Tübingen.
The Department of Gynecology at the University Hospital Tübingen
previously initiated its Senhance Surgical program in December of
2021, as announced by the Company on January 10, 2022. The system
will be initially utilized by the Department of Gynecology at the
University Hospital Tübingen. Independent of the lease and
utilization agreement, the Department of Gynecology at the
University Hospital Tübingen has entered into a research agreement
with the Company focused on collecting procedural and outcomes data
for certain gynecologic procedures performed with the Senhance
system.
“We are very excited to be partnering with the Department of
Gynecology at the University Hospital Tübingen, which is a leading
institution in Germany, and Europe more broadly,” said Anthony
Fernando, Asensus Surgical President, and CEO. “Tübingen’s
gynecological surgery department is one of the most well respected
in Europe, and we are proud they have decided to utilize Senhance
within their state-of-the-art facilities.”
Asensus Surgical's technology platform, Senhance Surgical
System, is the first of its kind digital laparoscopic platform that
leverages augmented intelligence to provide unmatched performance
and patient outcomes through machine learning. Senhance goes beyond
the typical surgical robotic systems, providing surgical assurance
through haptic feedback, eye-tracking camera control, and 3D
visualization, and is the first platform to offer 3mm instruments
(the smallest instrument available in the world on a robotic
surgical platform). The Senhance Surgical System is powered by the
Intelligent Surgical Unit™ (ISU™). The ISU enables machine
vision-driven control of the camera for a surgeon by responding to
commands and recognizing certain objects and locations in the
surgical field, and allows a surgeon to change the visualized field
of view using the movement of their instruments.
“Gynecological procedures require a high level of precision and
safety while at the same time utilizing small instruments due to
the delicacy and size of the anatomy,” said Professor Diethelm
Wallwiener, Medical Director of the Department of Gynecology at
University Hospital Tübingen. “Senhance is a great addition to our
gynecology department as it provides unparalleled minimally
invasive surgery with the potential to use 3mm instruments as well
as innovative surgical intelligence with the addition of the
ISU.”
About the Department of Gynecology at the University
Hospital Tübingen
The Department of Gynecology at the University Hospital Tübingen
is one of the 35 university hospitals in Germany that contribute to
the successful combination of high-performance medicine, research,
and teaching. They are a reliable partner in four of the six German
Centres for Health Research initiated by the Federal Government.
They welcome patients from all over the world who are treated in
their clinics and wish to benefit from their high standards in
research, patient care and nursing.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. This
builds upon the foundation of Digital Laparoscopy with the Senhance
Surgical System powered by the Intelligent Surgical Unit (ISU) to
increase surgeon control and reduce surgical variability. With the
addition of machine vision, augmented intelligence, and deep
learning capabilities throughout the surgical experience, we intend
to holistically address the current clinical, cognitive and
economic shortcomings that drive surgical outcomes and value-based
healthcare. Learn more about Performance-Guided Surgery and Digital
Laparoscopy with the Senhance Surgical System here:
www.senhance.com. Now available for sale in the US, EU, Japan,
Russia, and select other countries. For a complete list of
indications for use, visit: www.senhance.com/indications. For
more information, visit www.asensus.com.
Follow Asensus
- Email Alerts: https://ir.asensus.com/email-alerts
- LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
- Twitter: https://twitter.com/AsensusSurgical
- YouTube: https://www.youtube.com/c/transenterix
- Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and the Department of Gynecology at the University
Hospital Tübingen initiating a program with the Senhance System.
These statements and other statements regarding our future plans
and goals constitute "forward looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
Senhance Surgical System will be a great addition to the Department
of Gynecology at the University Hospital Tübingen, providing
unparalleled minimally invasive surgery with the potential to use
3mm instruments as well as innovative surgical intelligence with
the addition of the ISU. For a discussion of the risks and
uncertainties associated with the Company’s business, please review
our filings with the Securities and Exchange Commission (SEC),
including our Annual Report on Form 10-K for the year ended
December 31, 2021, filed with the SEC on February 28, 2022 and our
other filings we make with the SEC. You are cautioned not to place
undue reliance on these forward looking statements, which are based
on our expectations as of the date of this press release and speak
only as of the origination date of this press release. We undertake
no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
INVESTOR CONTACT:Mark Klausner or Mike Vallie,
443-213-0499invest@asensus.com
MEDIA CONTACT:Lauren Stredler, 847-271-6891CG
Lifelstredler@cglife.com
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024